Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

MIDAS: a Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents

A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints.

MIDAS-2: an Enhanced Bayesian Platform Design for Immunotherapy Combinations with Subgroup Efficacy Exploration.

A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Shotgun: A Bayesian Seamless Phase I-II Design to Accelerate the Development of Targeted Therapies and Immunotherapy.

A Bayesian Phase I/II Trial Design for Immunotherapy

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Bayesian Phase II Adaptive Randomization by Jointly Modeling Time-to-event Efficacy and Binary Toxicity

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

SPIRIT: A Seamless Phase I/II Randomized Design for Immunotherapy Trials

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints

BOIN: a Novel Bayesian Design Platform to Accelerate Early Phase Brain Tumor Clinical Trials

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy